-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 20, Hengrui Medicine issued an announcement stating that it had recently received approval from the State Food and Drug Administration to issue a "Drug Clinical Trial Approval Notice" for ivabradine hydrogen sulfate sustained-release tablets, and clinical trials will be launched in the near future.
Indications: This product is suitable for NYHAII~IV chronic heart failure patients with sinus rhythm, heart rate ≥70 beats/min, and cardiac systolic dysfunction.
Ivabradine is a pure heart rate-lowering drug, which reduces the heart rate by selectively and specifically inhibiting the If current of cardiac pacing.
Upon inquiry, similar products in Europe, such as Ivabradine Anpharm and Ivabradine Accord, have been approved.
Upon inquiry, the global sales of ivabradine tablets in 2019 were US$379 million.